GeoVax Labs Inc. (NASDAQ:GOVX) Stock Short Interest Report for September

GeoVax Labs Inc. (NASDAQ:GOVX) was the target of a significant drop in short interest during the month of September. As of September 30th, there was short interest totaling 281,773 shares, a drop of 43.5% from the September 15th total of 498,698 shares. Based on an average daily volume of 241,876 shares, the short-interest ratio is presently 1.2 days. Currently, 3.8% of the company’s stock are sold short.

GeoVax Labs Price Performance

NASDAQ GOVX traded up $0.00 on Thursday, hitting $0.24. 577,092 shares of the company were exchanged, compared to its average volume of 1,913,438. The firm has a market capitalization of $1.81 million, a P/E ratio of -0.02 and a beta of 3.69. GeoVax Labs has a twelve month low of $0.23 and a twelve month high of $15.75. The company’s 50 day moving average price is $0.49 and its 200-day moving average price is $1.07.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings results on Monday, July 27th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($2.16) by $1.19. As a group, equities analysts expect that GeoVax Labs will post -4.94 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on GOVX shares. Noble Financial reaffirmed an “outperform” rating on shares of GeoVax Labs in a research report on Tuesday, September 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Friday, July 17th. Finally, Wall Street Zen raised GeoVax Labs from a “sell” rating to a “hold” rating in a research note on Sunday, June 21st. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, GeoVax Labs currently has an average rating of “Hold” and a consensus target price of $150.00.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a biotechnology company focused on developing vaccines and immunotherapies for infectious diseases and cancer. The company’s research is based primarily on a vaccine platform that combines a modified vaccinia Ankara (MVA) viral vector with virus-like particles (VLPs) to stimulate both antibody and cellular immune responses.

GeoVax’s development programs have included GEO-CM04S1, a next-generation COVID-19 vaccine candidate; GOVX-B11, an investigational HIV vaccine designed to generate broadly protective immune responses; and GOVX-CHIKV, a vaccine candidate targeting chikungunya virus.